TB-500 is one of the most widely studied peptides in tissue-repair and recovery research, frequently examined alongside BPC-157. This article provides an educational overview of what the published scientific literature reports about TB-500, its structure, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is TB-500?
TB-500 is a synthetic peptide based on a segment of thymosin beta-4 (Tβ4) — a naturally occurring protein found in virtually all human and animal cells, originally isolated from thymus tissue. Research literature notes that TB-500 features an acetylated N-terminus, which studies indicate contributes to its stability. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in TB-500 centres on its relationship with actin, a key structural protein involved in cell movement. The published literature describes its study in relation to:
- Actin regulation — research describes TB-500 as an actin-sequestering molecule, a mechanism central to cell migration and tissue repair.
- Cell migration and tissue regeneration — studies examine its role in moving cells to areas of tissue damage in research models.
- Angiogenesis — research has investigated its association with new blood-vessel formation.
- Inflammatory modulation — studies in experimental models have explored its effect on inflammatory signalling.
Because its mechanism (actin regulation) differs from BPC-157's, the two are often studied together as complementary research models in tissue repair.
What the research has reported
Much of the published TB-500 research is preclinical, spanning wound-healing, corneal, cardiac and other tissue models. The broader thymosin beta-4 molecule it derives from has been the subject of some clinical investigation. Researchers note that, as with many research peptides, large-scale human clinical data on TB-500 specifically remains limited, and the published findings are primarily from laboratory and animal models.
Regulatory status in Australia
TB-500 has not been approved by the Therapeutic Goods Administration (TGA), is not listed on the Australian Register of Therapeutic Goods (ARTG), and is not approved for therapeutic use. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. TB-500 is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.